Zacks Investment Research lowered shares of Seres Therapeutics (NASDAQ:MCRB) from a buy rating to a hold rating in a research report released on Wednesday, January 3rd.

According to Zacks, “Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “

A number of other brokerages have also recently issued reports on MCRB. ValuEngine cut shares of Seres Therapeutics from a hold rating to a sell rating in a research note on Thursday, September 21st. Cowen reissued a buy rating on shares of Seres Therapeutics in a research note on Monday, October 2nd. Seaport Global Securities reissued a buy rating and issued a $20.00 price objective on shares of Seres Therapeutics in a research note on Friday, October 6th. CIBC started coverage on shares of Seres Therapeutics in a research note on Friday, October 13th. They issued an outperform rating and a $19.00 price objective for the company. Finally, Oppenheimer started coverage on shares of Seres Therapeutics in a research note on Thursday, October 12th. They set an outperform rating and a $19.00 target price for the company. Two analysts have rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus price target of $18.00.

Seres Therapeutics (MCRB) opened at $10.76 on Wednesday. The company has a debt-to-equity ratio of 0.11, a current ratio of 6.53 and a quick ratio of 6.53. Seres Therapeutics has a 52-week low of $8.85 and a 52-week high of $17.42.

Seres Therapeutics (NASDAQ:MCRB) last released its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.17) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.39) by $0.22. The business had revenue of $23.00 million for the quarter, compared to the consensus estimate of $17.29 million. Seres Therapeutics had a negative net margin of 267.15% and a negative return on equity of 82.11%. The company’s quarterly revenue was up 76.9% on a year-over-year basis. During the same period last year, the firm earned ($0.46) earnings per share. research analysts forecast that Seres Therapeutics will post -2.33 EPS for the current year.

A number of hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its position in Seres Therapeutics by 1.2% during the second quarter. Vanguard Group Inc. now owns 1,585,026 shares of the biotechnology company’s stock valued at $17,911,000 after purchasing an additional 19,363 shares during the last quarter. Ark Investment Management LLC lifted its position in Seres Therapeutics by 21.5% during the second quarter. Ark Investment Management LLC now owns 765,191 shares of the biotechnology company’s stock valued at $8,647,000 after purchasing an additional 135,276 shares during the last quarter. JPMorgan Chase & Co. lifted its position in Seres Therapeutics by 39.9% during the third quarter. JPMorgan Chase & Co. now owns 373,334 shares of the biotechnology company’s stock valued at $6,160,000 after purchasing an additional 106,479 shares during the last quarter. State Street Corp lifted its position in Seres Therapeutics by 12.0% during the second quarter. State Street Corp now owns 321,699 shares of the biotechnology company’s stock valued at $3,637,000 after purchasing an additional 34,393 shares during the last quarter. Finally, Northern Trust Corp lifted its position in Seres Therapeutics by 16.2% during the second quarter. Northern Trust Corp now owns 235,766 shares of the biotechnology company’s stock valued at $2,664,000 after purchasing an additional 32,875 shares during the last quarter. Institutional investors and hedge funds own 75.83% of the company’s stock.

WARNING: This story was reported by Marea Informative and is owned by of Marea Informative. If you are reading this story on another website, it was copied illegally and reposted in violation of US and international copyright & trademark legislation. The original version of this story can be accessed at https://www.mareainformativa.com/2018/01/30/seres-therapeutics-mcrb-stock-rating-lowered-by-zacks-investment-research-updated-updated-updated.html.

About Seres Therapeutics

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

Get a free copy of the Zacks research report on Seres Therapeutics (MCRB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.